Muromonab-Cd3
Lymphoblastic Leukemia, Acute, Childhood;
St. Anna Kinderkrebsforschungmonoclonal_antibodyPhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Lymphoblastic Leukemia, Acute, Childhood; cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ETOPOSIDE National Cancer Institute (NCI) | Phase 3 | BB |
Treosulfan Fred Hutchinson Cancer Center | Phase 3 | BB |
Same molecule, other indications
Muromonab-Cd3 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →